Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-25 @ 5:19 AM
Ignite Modification Date:
2025-12-26 @ 4:26 AM
NCT ID:
NCT04305327
Pre Assignment Details:
In the 12 weeks Induction Period (Week 0 to Week 12) participants were assigned to brodalumab, ustekinumab or placebo. This was followed by a Maintenance Period of 40 weeks (Week 12 to Week 52) where those receiving ustekinumab or brodalumab continued with the same medication whereas participants on placebo were switched to either brodalumab or ustekinumab.
Recruitment Details:
Participants were recruited across countries in Europe (Belgium, Germany, Hungary, Italy, Poland, Spain) from December 2022 to May 2023 when the study was early terminated.
Study:
NCT04305327
Study Brief:
Results Section:
NCT04305327